Recent Insider Transactions • Mar 26
Independent Non-Executive Chairman recently bought AU$58k worth of stock On the 23rd of March, Manik Pujara bought around 3m shares on-market at roughly AU$0.017 per share. This transaction amounted to 61% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Manik's only on-market trade for the last 12 months. 공지 • Feb 02
Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million. Peak Processing Limited has completed a Follow-on Equity Offering in the amount of AUD 2.72 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 150,000,000
Price\Range: AUD 0.017
Discount Per Security: AUD 0.00102
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,000,000
Price\Range: AUD 0.017
Discount Per Security: AUD 0.00102
Transaction Features: Subsequent Direct Listing 공지 • Jan 20
Peak Processing Limited Announces Cessation of Employment of Brian Mbesha as CFO, Effective January 20, 2026 Peak Processing Limited announced the immediate cessation of employment of its Canadian-based Chief Financial Officer (CFO), Mr. Brian Mbesha, as part of an internal restructure. This change forms part of a broader and ongoing cost optimisation program focused on strengthening financial discipline and supporting improved operational execution. Financial oversight, reporting, and controls will continue uninterrupted, led by the Company’s existing finance team, with additional interim part-time assistance from an experienced Australian-based external professional services firm accustomed to Australian reporting requirements to fulfil the CFO functions and ensure compliance and continuity during this transition period. Effective immediately on January 20, 2026. Board Change • Jan 01
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Matt Adams is the most experienced director on the board, commencing their role in 2025. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 01
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman of the Board Vaughan Webber is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 05
Full year 2025 earnings released: AU$0.009 loss per share (vs AU$0.069 loss in FY 2024) Full year 2025 results: AU$0.009 loss per share (improved from AU$0.069 loss in FY 2024). Revenue: AU$15.5m (up 27% from FY 2024). Net loss: AU$4.84m (loss narrowed 81% from FY 2024). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Oct 03
Insider recently sold AU$201k worth of stock On the 1st of October, Joshua Fegan sold around 11m shares on-market at roughly AU$0.019 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$157k more than they bought in the last 12 months. 공지 • Oct 01
Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025 Althea Group Holdings Limited, Annual General Meeting, Nov 27, 2025. 공지 • Sep 17
Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million. Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.55 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 141,666,667
Price\Range: AUD 0.018
Discount Per Security: AUD 0.00108
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$8.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.0m free cash flow). Negative equity (-AU$574k). Earnings have declined by 5.7% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$18.6m market cap, or US$12.2m). New Risk • Jul 31
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$21.4m market cap, or US$13.8m). New Risk • Apr 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Market cap is less than US$10m (AU$11.0m market cap, or US$6.55m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). 공지 • Feb 19
Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Althea Group Holdings Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 119,000,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 6,000,000
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Transaction Features: Subsequent Direct Listing 공지 • Feb 17
Althea Group Holdings Limited Appoints Matt Adams as Non-Executive Director Althea Group Holdings Limited announced the appointment of Mr. Matt Adams as a Non-Executive Director, effective 17 February 2025. Mr. Adams is an experienced finance professional with over 25 years of executive-level experience across corporate finance, restructuring, and turnaround sectors. He has held senior leadership positions, including CEO, CFO, and CRO roles for both listed and unlisted entities. He is currently the Managing Director of Dynamic Corporate Investments, a boutique corporate finance firm specialising in restructuring, corporate advisory, and investment. Mr. Adams' extensive background in financial structuring, governance, and risk management will provide valuable strategic insights to AGH as the Company continues to execute its growth initiatives. New Risk • Feb 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.7m (US$9.05m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (AU$14.7m market cap, or US$9.05m). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding). 공지 • Jan 31
Althea Group Holdings Limited Announces Penelope Dobson Intention to Retire as Director Althea Group Holdings Limited announced that Penelope Dobson has advised her intention to retire as director at the annual general meeting to be held on January 31, 2025. 공지 • Dec 30
Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025 Althea Group Holdings Limited, Annual General Meeting, Jan 31, 2025. New Risk • Dec 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (AU$17.3m market cap, or US$11.2m). 공지 • Oct 30
Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH). Montu Group UK Ltd agreed to acquire MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) for AUD 1 million on October 17, 2024.
The completion is subject to the following conditions precedent: Transfer of patient information; Execution of an IP Assignment Deed for the assignment of intellectual property rights o Provision and verification of data relating to patient numbers; Completion will occur 5 business days from the date on which the above conditions have been satisfied (or waived by Montu UK); and The Asset Sale Deed otherwise contains terms customary for a transaction of this nature, including in relation to representations and warranties and and is expected to complete in the coming weeks.
Montu Group UK Ltd completed the acquisition of MyAccess Clinics business in the UK and Ireland of Althea Group Holdings Limited from Althea Group Holdings Limited (ASX:AGH) on October 29, 2024. Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.085 loss per share (vs AU$0.039 loss in FY 2023) Full year 2024 results: AU$0.085 loss per share (further deteriorated from AU$0.039 loss in FY 2023). Revenue: AU$30.4m (up 21% from FY 2023). Net loss: AU$32.1m (loss widened 134% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings. 공지 • Aug 21
Althea Group Holdings Limited Announces Board Changes 19 August 2024: Althea Group Holdings Limited announced that Mr. Andrew Newbold will step down from his position as Non- Executive Director and Chairman of the Board on 29 August 2024, following a scheduled board meeting. Mr. Vaughan Webber will then assume the role of Chairman, effective immediately on conclusion of this meeting. Mr. Newbold has served as Non-Executive Director and Chairman since September 2018, providing exemplary leadership and guidance during a period of significant growth and transformation for AGH. The Board extend its sincere thanks to Mr. Newbold for his dedication, strategic vision, and commitment to the Company. We wish him all the best in his future endeavours. The Board announced the appointment of Mr. Vaughan Webber as the new Non-Executive Director and Chairman of Althea Group Holdings Ltd, effective immediately upon Mr. Newbold's resignation on 29 August 2024. Mr. Webber is a seasoned company director and finance executive with over 20 years of experience, possessing an in-depth understanding of ASX-listed company operations and governance. His career highlights include: Non-Executive Director, HUB24 Ltd. (2012-2018): Joined during a board restructure to help recapitalise the business, divest non-performing divisions, and support the CEO and management team in developing a robust strategy. Independent Chairman, Wentworth Holdings Ltd. (2009-2013): Oversaw the company's restructuring, the sale of its primary business operations, and the subsequent acquisition by Thorney Opportunities Ltd. 공지 • Jul 17
Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million. Althea Group Holdings Limited has completed a Follow-on Equity Offering in the amount of AUD 2.026662 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 101,333,100
Price\Range: AUD 0.02
Discount Per Security: AUD 0.0012
Transaction Features: Subsequent Direct Listing 공지 • Jan 05
Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024 Althea Group Holdings Limited, Annual General Meeting, Jan 30, 2024, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors's report and auditor's report for the Company for the financial year ended 30 June 2023; to consider the Remuneration Report; to consider the Additional 10% Placement Capacity; to consider the Re-election of Directors; to consider Short Term Incentive - Grant of Performance Rights to Joshua Fegan; to consider the Long Term Incentive - Grant of Performance Rights to Joshua Fegan; and to consider any other business that may be lawfully brought forward. New Risk • Nov 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$7.8m free cash flow). Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (AU$15.4m market cap, or US$10.1m). Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.04 loss in FY 2022) Full year 2023 results: AU$0.039 loss per share. Revenue: AU$25.1m (up 22% from FY 2022). Net loss: AU$13.7m (loss widened 13% from FY 2022). New Risk • Aug 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$16.3m market cap, or US$10.5m). 공지 • Jul 24
Althea Group Holdings Limited Announces Approval for Althea CBD12:THC10 for Reimbursement in Ireland Althea Group Holdings Limited announced that Ireland's Primary Care Reimbursement Service (`PCRS') has approved Althea CBD12:THC10 for reimbursement in Ireland. In a follow up to the Company's ASX announcement on 20 May 2022, Althea CBD12:THC10 has now been added to the PCRS in the Republic of Ireland, making it free of charge for Irish patients. The Rapid Review Submission for Althea CBD12:THC10 cannabis oil (50 ml), as included in Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023, has resulted in the assignment of administrative codes to facilitate access to the product in line with the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) for the specified therapeutic indications below, with an effective date of 1st August 2023: Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions; Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes. The agreed reimbursement price for Althea CBD12:THC10 (50ml) is 327.89, or approximately AUD 540. Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS). The onset of the disease is typically between 20 to 40 years of age, and up to 9,000 people live with this chronic condition in Ireland. Approximately 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy. 공지 • Feb 03
Althea Group Holdings Limited announced that it has received AUD 2.2 million in funding from Obsidian Global Partners, LLC Althea Group Holdings Limited announced that it has issued unsecured convertible notes for gross proceeds of AUD 2,200,000 on February 3, 2023. The transaction included participation from institutional investor Obsidian Global Partners, LLC. The notes are convertible at a conversion price of $1.5 (AUD 2.1153) into 54,206,846 common shares of the company. The company will pay no interest on the notes. The investor may in its discretion elect to convert one or more convertible securities at the relevant conversion price by providing the company notice, provided that, where an issue of shares would result in the voting power in the company of the investor or any other person exceeding 19.99%.The notes will mature twelve months from the date which is five business days from the date of execution of the relevant agreement. The company also issued 4,800,000 options with an an exercise price equal to 200% of the 5 actual trading days immediately prior to mutual execution of the relevant agreement. The company will pay fee of 6% of the purchase price and AUD 15,000 upfront as legal cost of the transaction. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 공지 • Nov 07
Althea Group Holdings Limited, Annual General Meeting, Nov 29, 2022 Althea Group Holdings Limited, Annual General Meeting, Nov 29, 2022, at 17:00 AUS Eastern Standard Time. Agenda: To receive the financial statements, Directors' report and auditor's report for the Company for the financial year ended 30 June 2022; to consider approval for Additional 10% Placement Capacity; to consider re-election of Directors; and to consider other matters. 공지 • Sep 15
Althea Group Holdings Limited Launches Next Generation Products Althea Group Holdings Limited announce its medical cannabis business Althea, has launched two innovative new products to meet patient needs. Commencing with Althea CBD25, Althea has released an exclusive range of soft gelatine capsules (`soft gel capsules') containing Althea's trusted full-spectrum cannabis extract, manufactured to EU-GMP standard. Each capsule of Althea CBD25 contains 25mg of cannabidiol (CBD), and less than 0.25mg of delta-9- tetrahydrocannabinol (THC) per capsule. As a full-spectrum product, Althea CBD25 also contains terpenes, flavonoids and other phytochemicals. Phytochemicals including cannabinoids and terpenes may have synergistic effects, a hypothesis often referred to as the `entourage effect'. Althea's unique range of soft gel capsules are administered orally, offering a gradual onset and extended duration of effect, compared to the rapid onset and shorter duration of effect for products requiring inhalation (dried flower products). In vitro studies have demonstrated effective disintegration of Althea soft gel capsules in less than 10 minutes and there is no significant difference in pharmacokinetic properties expected for patients converting to soft gel capsules from Althea's first generation (or other suppliers') bottled oil products. Why launch Althea CBD25 soft gel capsules?: Solid oral dosage formats are the gold-standard pharmaceutical preparation globally and are widely recognised for maximising patient acceptability and compliance. A consumer preference survey of soft gel capsules versus conventional solid oral dosage forms identified soft gel capsules as the first choice of delivery format. First generation bottled cannabis oils remain a challenge for patients with visual or dexterity impairments, taste intolerances and for patients residing in aged care facilities and hospitals (where medicines are allocated and dispensed). Althea soft gel capsules provide familiarity, convenience and confidence for doctors and patients, delivering precise and standardised dosing of the medicine. The release of soft gel capsules will continue to position Althea as a leader and innovator in the global medical cannabis industry. Schedule 3 Pharmacist only medicine (Australia): Subject to required regulatory approvals, Althea CBD25 soft gel capsules are a candidate to be supplied under the Therapeutic Goods Administration's (TGA) Schedule 3 (Pharmacist Only Medicine) entry for eligible CBD products. This new, non-prescription cannabis channel could allow Australian patients to purchase Althea CBD25 over the counter upon consultation with a pharmacist, without the need for a prescription. What is Althea THC25 dried flower?: Althea THC25 is a new and exclusive ultra-high THC cannabis dried flower product, containing 25% THC and less than 1% of CBD. Greenhouse grown in Canada and produced to meet the stringent standards of a pharmaceutical preparation for inhalation, Althea THC25 also retains a rich terpene and flavonoid profile. Althea THC25 is Althea's highest-concentrated THC dried flower product and will be available across all its `core' international medical cannabis markets (including Germany, UK and Australia). Why launch Althea THC25 dried flower?: Althea has until now focussed primarily on cannabis extracts, however, with a growing number of consumers accessing cannabis dried flower products via the medical framework, Althea THC25 has been introduced to capitalize on this sizeable market opportunity. Market data indicates that dried flower cannabis is the fastest growing product category in Australia and now accounts for 50.6% of the total market (+450% annual growth). The dried flower market is primarily driven by highly concentrated THC products, representing just over half of the total dried flower category. Althea THC25, the first of three new planned dried flower offerings, will be launched globally and supported by Althea's infield sales team, which will focus on educating the 1,400+ registered prescribers in the Althea network. Reported Earnings • Sep 01
Full year 2022 earnings released: AU$0.04 loss per share (vs AU$0.061 loss in FY 2021) Full year 2022 results: AU$0.04 loss per share (up from AU$0.061 loss in FY 2021). Revenue: AU$20.5m (up 78% from FY 2021). Net loss: AU$12.1m (loss narrowed 19% from FY 2021). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. 공지 • May 20
Health Products Regulatory Authority Approves Althea CBD12:THC10 Product of Althea Group Holdings Limited Althea Group Holdings Limited announced that the Health Products Regulatory Authority has approved Althea CBD12:THC10 product for prescription and supply in the Republic Ireland. Details: Althea is to enter the Irish medicinal cannabis market following the approval of Althea CBD12:THC10 by Ireland's medicines regulator, HPRA and the Minister for Health. Althea CBD12:THC10 is one of a limited number of medicinal cannabis products available for prescription and supply in the Republic of Ireland. The Company is seeking further product approvals in Ireland. An application will follow for Althea CBD12:THC10 to be added to the Primary Care Reimbursement Service in the Republic of Ireland as part of the Medicinal Cannabis Access Programme (MCAP), making it free of charge for Irish patients prescribed the treatment under the Medicinal Cannabis Access Programme. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Non-Executive Director Jakob Ripshtein was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Nov 24
No longer forecast to breakeven The analyst covering Althea Group Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of AU$5.00m in 2023. New forecast suggests the company will make a loss of AU$100.0k in 2023. Reported Earnings • Sep 01
Full year 2021 earnings released: AU$0.06 loss per share (vs AU$0.064 loss in FY 2020) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2021 results: Revenue: AU$11.5m (up 128% from FY 2020). Net loss: AU$15.0m (loss widened 1.9% from FY 2020). 공지 • Aug 25
Althea Group Holdings Limited announced that it expects to receive AUD 10.644452 million in funding Althea Group Holdings Limited announced a private placement of 44,351,885 common shares at an issue price of AUD 0.24 per share for gross proceeds of AUD 10,644,452.40 on August 25, 2021. The transaction will include participation from from existing institutional shareholders, new institutional investors and new sophisticated investors. The transaction is expected to close on August 31, 2021. Price Target Changed • May 06
Price target decreased to AU$1.13 Down from AU$1.48, the current price target is provided by 1 analyst. New target price is 169% above last closing price of AU$0.42. Stock is up 6.3% over the past year. Reported Earnings • Mar 02
First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.037 loss in 1H 2020) The company reported a solid first half result with improved revenues and control over costs, although losses were not reduced. First half 2021 results: Revenue: AU$5.10m (up 175% from 1H 2020). Net loss: AU$8.27m (flat on 1H 2020). 공지 • Feb 11
Althea Group Holdings Limited Completes the Export of Its First Commercial Shipment of Althea Products to UK-Based Medicinal Cannabis Distributor Grow Pharma Group Althea Group Holdings Limited announced that it has completed the export of its first commercial shipment of Althea products to UK-based medicinal cannabis distributor Grow Pharma Group (`Grow Pharma'). A medicinal cannabis supply agreement was signed by the two parties last year, allowing Grow Pharma to distribute Althea products in the UK, in parallel to the Company's own existing sales channel. Following initial success with products supplied to Grow Pharma from its UK inventory, Althea recently expanded its agreement with Grow Pharma to include two further jurisdictions, including the Isle of Man and Guernsey. The Isle of Man and Guernsey are self-governing dependencies of the Crown and medicinal cannabis has been legal in both territories since 2018 and 2019, respectively. 공지 • Feb 10
Althea Group Holdings Limited Completes First Shipment of Products to Germany Althea Group Holdings Limited announced that it has completed its first shipment of Althea medicinal cannabis oil products to the Company's local partner in Germany, Nimbus Health GmbH (`Nimbus'). The initial shipment of Althea medicinal cannabis oil products valued at approximately $1,000,000 (EUR 640,000) has arrived at the Nimbus facility and will be distributed through a large network of existing partnering pharmacies. In conjunction with Nimbus, Althea will generate its own sales via new and existing customers and will not rely on third party wholesalers for repeat purchase orders. Exclusive supply & distribution agreement: Althea announced a Memorandum of Understanding in November 2019, followed by a Supply and Distribution Agreement in May 2020. Under the agreement, Althea will receive payment for products supplied to Nimbus, along with 50% of net profit. In addition, Althea will retain ownership of all real-world anonymized patient data collected through its industry-leading medical app, Althea ConciergeTM. To launch the Althea brand in Germany, Nimbus is adopting the same successful market access strategy implemented by the Company in Australia and the UK. 공지 • Dec 18
Althea Group Holdings Limited Announces Availability of CBD Medicines For Over-The-Counter Sale from 2021 Althea Group Holdings Limited announced that a major regulatory change has been confirmed in relation to the status of cannabidiol (CBD) in Australia. TGA confirms new Schedule 3 entry for CBD The Therapeutic Goods Administration issued its final decision on proposed amendments to the Poison Standard which, amongst other amendments, sees a new Schedule 3 entry created for cannabidiol. The date of effect of the decision is 1 February 2021, bringing it forward from the date of 1 June 2021 as proposed in the interim decision. The amendment will allow CBD to be supplied for therapeutic use under a new Schedule 3 (Pharmacist Only Medicine) entry. This new, non-prescription cannabis channel would allow Australian patients to purchase CBD products over the counter upon consultation with a pharmacist, without the need for a prescription. Maximum recommended daily dose increased The final decision included a modification to the dose specified in the interim decision, increasing from 60 mg/day, up to 150 mg/day. The decision paves the way for Althea's top selling full-spectrum CBD product, Althea CBD100, to be made available under Schedule 3 (currently sold in Schedule 4 - Prescription Only Medicine). Althea CBD100, along with several other CBD preparations currently in development, would need to be included in the Australian Register of Therapeutic Goods (ARTG) to be made available for sale as Schedule 3 products. The Company maintains robust drug master files for its medications and is confident in its ability to meet the ARTG requirements for Schedule 3 preparations. 공지 • Dec 16
Althea Group Holdings Limited announced that it expects to receive AUD 6 million in funding Althea Group Holdings Limited (ASX:AGH) announced a private placement of 13,636,364 common shares at an issue price of AUD 0.44 per share for gross proceeds of AUD 6,000,000 on December 14, 2020. The transaction is expected to close December 21, 2020. The transaction will include participation from to institutional, sophisticated and professional investors. 공지 • Jun 22
Althea Group Holdings Limited(ASX:AGH) dropped from S&P/ASX Emerging Companies Index Althea Group Holdings Limited(ASX:AGH) dropped from S&P/ASX Emerging Companies Index